The TERTIO trial will propose to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine (UCPVax) with anti-PD-L1 therapy (atezolizumab) and bevacizumab in unresectable HCC by evaluation of the objective response rate at 6 months (randomized phase II, 10 centers, 105 patients)
Signed informed consent
Histologically confirmed hepatocellular carcinoma
Locally advanced, metastatic, or unresectable disease
Patient who had not previously received systemic anti-cancer treatment
Patients previously exposed to anti-tumor immunotherapy as anti-PD-1, anti-PD-L1, or anti-CTLA4 agent or any immune therapy.
Diagnosis of additional malignancy within 3 years prior to the inclusion with the exception of curatively treated basal cell carcinoma of the skin and/or curatively resected in situ cervical or breast cancer
Patient with any medical or psychiatric condition or disease, which would make the patient inappropriate for entry into this study
Current participation in a study of an investigational agent or in the period of exclusion
Centre Hospitalier Universitaire de Besancon
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborator
PRODIGE
Collaborator